SUNITCAP 12.5 mg contains Sunitinib malate, an oral targeted anticancer medicine. It is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks receptors involved in tumor growth, angiogenesis (blood vessel formation), and cancer cell survival, thereby slowing disease progression.

Sunitinib is indicated for treatment of:

1. Gastrointestinal Stromal Tumor (GIST)
      – After disease progression or intolerance to imatinib

2. Advanced Renal Cell Carcinoma (RCC)

3. Pancreatic Neuroendocrine Tumors (pNETs)
      – Unresectable or metastatic, well-differentiated

Common side effects:

•  Fatigue and weakness

•  Diarrhea

•  Nausea, vomiting

•  Loss of appetite, weight loss

•  High blood pressure

•  Hand–foot syndrome

•  Mouth sores

•  Hair or skin color changes

Serious side effects:

•  Heart problems (reduced LVEF, heart failure)

•  Severe hypertension

•  Thyroid dysfunction (hypothyroidism)

•  Bleeding or thromboembolic events

•  Liver toxicity

 Regular monitoring of blood pressure, thyroid function, liver function, and cardiac status is required.

Dosage depends on indication and patient tolerance.

Common dosing regimens:

•  50 mg once daily for 4 weeks ON, 2 weeks OFF (6-week cycle)

•  37.5 mg once daily continuously (especially in pNETs)

 The 12.5 mg strength is used for dose titration or dose reduction based on tolerance.


NOTE: This medicine should be taken only under a doctor’s supervision.